• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Medical Accessories Inc 04-Feb-02


Public Health Service

Central Region

Food and Drug Administration

Waterview Corporate Center

10 Waterview Blvd., 3rd Floor

Parsippany, NJ 07054

Telephone (973) 526-6008

February 4, 2002




File # 02-NWJ-17

Mr. Janis Ziedonis


Medical Accessories, Inc.

92 Youngs Rd.

Trenton, NJ 086 19

Dear Mr. Ziedonis,

During an inspection of your firm located at 92 Youngs Road, Trenton, NJ on December

27, 2001 and January 2 and 9, 2002, an investigator from the Food and Drug

Administration (FDA) determined that you are a manufacturer of Sterile Fetal Scalp

Electrodes. Sterile Fetal Scalp Electrodes are considered to be class II medical devices

within the meaning of section 201(h) of the Federal Food Drug and Cosmetic Act (the Act).

Our inspection determined that your firm is not in compliance with the Quality System

Regulations (QSR) as required by Title 21 Code of Federal Regulations Part 820

concerning medical devices, which renders them adulterated within the meaning of section 501(h) of the Act as follows:

  1. Failure to establish and maintain procedures for implementing corrective and preventive actions that include requirements for analyzing sources of quality data to identify existing and potential quality problems as required by 21 CFR 820.100.
  2. Failure to establish Medical Device Reporting (MDR) procedures as required by 21 CFR 820.198(a).
  3. Failure to have documented validation of the package sealing process as well as the Re-sterilization process as required by 21 CFR 820.75.
  4. Failure to calibrate the thermal sealer time and temperature settings as required by 21 CFR 820.72.
  5. Failure to include the primary identification label and labeling used for each production unit in the device history record as required by 21 CFR 820.184 (e).

We have received and reviewed your firm? s responses to the Inspectional Observations

(Form FDA 483). The responses were found to be inadequate. The response to FDA-483

Item #l addresses problems found by the production operators, but does not address other

sources of quality data such as quality audit reports, quality records, service records,

complaints, and returned product. The response to FDA-483 item #2 includes a device

master record for fetal scalp electrodes and does not address the observation of lack of a

medical device reporting (MDR) procedure. The response to FDA-483 item #3 does not

include data to show that a process validation of the pouch sealing process was performed. The response to FDA-483 item #4 states that the correction has already been implemented but did not include supporting documentation. Your response has been made part of the New Jersey District file.

This letter is not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure adherence to each requirement of the Act and regulations. The specific violations noted in this letter and on the Form FDA483 issued at the conclusion of the inspection may be symptomatic of serious underlying problems within your establishment?s quality system. You are responsible for investigating and determining the causes of the violations identified by the FDA. If the causes are determined to be system problems, you must promptly initiate permanent corrective and preventive actions.

Federal agencies are advised of the issuance of all Warning letters about devices so that

they may take this information into account when considering the award of contracts.

Additionally, no premarket submissions for Class III devices to which the Quality

System/GMP deficiencies are reasonably related will be cleared or approved until the

violations have been corrected. Also, no requests for Certificates to Foreign Governments

will be approved until the violations related to the subject devices have been corrected.

You should take prompt action to correct the deviations identified above. Failure to

promptly correct these deviations may result in regulatory action being initiated by the

FDA without further notice. These actions include, but are not limited to, seizure,

injunction and/or civil penalties.

Please notify this office in writing within 15 working days of receipt of this letter, of the

specific steps you have taken to correct the noted violation, including an explanation of

each step being taken to identify and make corrections to any underlying system problems necessary to assure that similar violations will not recur. Your response should be directed to the New Jersey District, FDA, 10 Waterview Blvd., 3d Floor, Parsippany, New Jersey 07054, Attn: Frank Marciniak, Acting Compliance Officer.


Douglas I. Ellsworth

District Director

New Jersey District